V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Keros Therapeutics Executive Compensation (FY25)

KROS · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Jasbir Seehra
Latest say-on-pay support
=
June 3, 2026
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Keros Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 22, 2026Latest filing (8-K): June 3, 2026
8 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Keros Therapeutics brief$1,500Get the executive brief
Velarion Member, one year
175 figures on this page: 172 cited to the filing that reported them, 3 calculated from figures it prints. See the citations
This company is not required to report a chief executive pay ratio.

More on Keros Therapeutics

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Jasbir Seehra: $6,273,192 → $2,540,204 (59.5% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Keros Therapeutics' chief executive and what were they paid?
Jasbir Seehra was paid $2,540,204 in total compensation as President and Chief Executive Officer for fiscal 2025. Compared with the $6,273,192 reported for fiscal 2024, Seehra's total was 59.5% lower.
What was Keros Therapeutics' say-on-pay result?
Shareholders recorded 93.6% support for the say-on-pay proposal at the meeting held June 3, 2026 for fiscal 2025.
Which companies are in Keros Therapeutics' peer group?
The disclosed peer group includes Akero Therapeutics, Inc., Arcturus Therapeutics Holdings Inc., Celldex Therapeutics, Inc., Crinetics Pharmaceuticals, Inc. and Disc Medicine, Inc., among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jasbir Seehra
Chief Executive Officer and Director
◇◇—◇◇—◇◇
Christopher Rovaldi
Chief Operating Officer
◇——◇◇—◇◇
Simon Cooper
Chief Medical Officer
◇——◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jasbir Seehra
Chief Executive Officer and Chair
◇◇—◇◇—◇◇
Christopher Rovaldi
President and Chief Operating Officer
◇——◇◇—◇◇
Simon Cooper
M.B.B.S. Former Chief Medical Officer
◇——◇◇—◇◇
Keith Regnante
Chief Financial Officer
◇——◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Christopher Rovaldi
President and Chief Operating Officer
◇——◇◇—◇◇
Jasbir Seehra
Chief Executive Officer and Chair
◇——◇◇—◇◇
Yung Chyung
Chief Medical Officer
◇◇—◇◇——◇
Keith Regnante
Chief Financial Officer
◇——◇◇—◇◇
Simon Cooper
Former Chief Medical Officer
Departed during or after this year
◇——◇——◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jasbir Seehra
President and Chief Executive Officer
◇—◇—◇—◇◇
Christopher Rovaldi
Former President and Chief Operating Officer
Departed during or after this year
◇—◇———◇◇
Keith Regnante
Chief Financial Officer
◇—◇—◇—◇◇
Esther Cho
Chief Legal Officer and Secretary
◇—◇—◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Christopher RovaldiOTHER——————◇
Esther ChoOTHER——————◇
Jasbir SeehraOTHER——————◇
Keith RegnanteOTHER——————◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Keith RegnanteOption◇—◇2/12/2034
Option◇—◇2/15/2033
Option◇—◇1/20/2032
RSU◇◇——
Jasbir SeehraOption◇—◇2/15/2033
Option◇—◇2/12/2034
Option◇—◇1/20/2032
RSU◇◇——
PSU◇◇——
Esther ChoRSU◇◇——
Option◇—◇2/12/2034
Option◇—◇2/15/2033
Option◇—◇1/20/2032
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Christopher Rovaldi
Former President and Chief Operating Officer · Employment agreement · citing a 2022 filing
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Esther Cho
Chief Legal Officer and Secretary · Employment agreement · citing a 2025 filing
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Jasbir Seehra
President and Chief Executive Officer · Employment agreement
Severance multiple◇
Change-in-control multiple◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jean-Jacques Bienaimé
Board chair
◇◇◇———◇
Mary Ann Gray
◇◇◇———◇
Nima Farzan
◇◇◇———◇
Julius Knowles
◇◇◇———◇
Alpna Seth
◇◇◇———◇
Carl L. Gordon
◇◇◇———◇
Tomer Kariv
◇◇◇———◇
Ran Nussbaum
◇◇◇———◇
Charles Newton and Jasbir Seehra served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Akero Therapeutics, Inc. AKRO
  • Arcturus Therapeutics Holdings Inc. ARCT
  • Celldex Therapeutics, Inc. CLDX
  • Crinetics Pharmaceuticals, Inc. CRNX
  • Disc Medicine, Inc. IRON
  • Geron Corporation GERN
  • IDEAYA Biosciences, Inc. IDYA
  • Iovance Biotherapeutics, Inc. IOVA
  • KalVista Pharmaceuticals, Inc. KALV
  • Kura Oncology, Inc. KURA
  • Longboard Pharmaceuticals, Inc. LBPH
  • Pliant Therapeutics, Inc. PLRX
  • Protagonist Therapeutics, Inc. PTGX
  • Relay Therapeutics, Inc. RLAY
  • Replimune Group, Inc. REPL
  • Rocket Pharmaceuticals, Inc. RCKT
  • Scholar Rock Holding Corporation SRRK
  • SpringWorks Therapeutics, Inc. SWTX
  • Syndax Pharmaceuticals Inc. SNDX

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 3, 2026=◇◇◇
2024June 4, 2025=◇◇◇
2023May 30, 2024=◇◇◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Jasbir Seehra (President and Chief Executive Officer), FY2025 total compensation $2,540,204 (base salary $700,000) [exec_comp, SEC accession 0001104659-26-046791, filed 2026-04-22]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Tell me when Keros Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Keros Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Keros Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Keros Therapeutics' disclosed peer group is defensible, who names Keros Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
175 figures on this page: 172 cited to the filing that reported them, 3 calculated from figures it prints.
172 cited to the filing
3 calculated from the filing

Documents cited

  1. 0001664710-26-000034
  2. 0001104659-26-046791
    EXECUTIVE COMPENSATION · NON-EMPLOYEE DIRECTOR COMPENSATION · Non-Employee Director Compensation Policy · Outstanding Equity Awards as of December 31, 2025 · and 2 more sections
  3. 0001664710-25-000057
  4. 0001104659-25-037982
  5. 0001664710-24-000045
  6. 0001104659-24-048301
  7. 0001664710-22-000002
    EX-10.16
  8. 0001664710-25-000071
    EX-10.20
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Keros Therapeutics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/KROS (accessed 2026).
Short form: data: Velarion

The paid brief for Keros Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
8 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Keros Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Keros Therapeutics discloses

The companies named in KROS's own disclosed peer group.

Akero Therapeutics, Inc.Arcturus Therapeutics Holdings Inc.Celldex Therapeutics, Inc.Crinetics Pharmaceuticals, Inc.Disc Medicine, Inc.Geron CorporationIDEAYA Biosciences, Inc.Iovance Biotherapeutics, Inc.KalVista Pharmaceuticals, Inc.Kura Oncology, Inc.Longboard Pharmaceuticals, Inc.Pliant Therapeutics, Inc.Protagonist Therapeutics, Inc.Relay Therapeutics, Inc.Replimune Group, Inc.Rocket Pharmaceuticals, Inc.Scholar Rock Holding CorporationSpringWorks Therapeutics, Inc.Syndax Pharmaceuticals Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy